Baldandorj, Tuul
Loading...
Товч нэр
Baldandorj, Tuul
Бүтэн нэр
Baldandorj Tuul
Латин нэр
Baldandorj Tuul
Албан тушаал
Судлаач
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of IDH1 Mutation on Long-Term Survival in Patients with Diffuse Glioma(Mongolian National University of Medical Sciences, 2019-03-31) ;Enkhee Ochirjav; ;Gheeyoung ChoeObjectives: Diffuse brain gliomas are common primary brain tumor associated with a poor prognosis. In this study, we aimed to determine the impact of IDH1 mutation status on long term survival. Methods: Patients who underwent surgery for diffuse brain glioma were selected. Based on IDH1 mutation status, patients were separated into IDH1 mutant and IDH1 wildtype groups. Results: A total of 124 patients with diffuse brain tumor were included (mean age 39±17, 48.4% male). The frequency of IDH1 mutant and IDH1 wildtype were 56.5% (n=70) and 43.5% (n=54), respectively. During follow-up, 76 patients (61.3%) died and the median follow-up was 8 months (IQR 4; 16). Patients with IDH1 mutant more likely younger (36±16 vs. 43±17, p<.05) and had low grade (grade II) tumor (64.3% vs. 20.4%, p<.001). After adjustment of possible predictors, such age, gender, tumor location and surgical type, IDH1 mutant was an independent predictor of all-cause mortality (HR=0.43, 95% CI 0.26- 0.71, p<.001). Kaplan-Meier estimation showed IDH1 mutant is associated with longer survival compared with IDH1 wildtype in low grade tumor (log rank p<.001). Conclusion: Mutated IDH1 is an independent predictor of all-cause mortality in patients with diffuse brain glioma and resulted in longer survival compared with IDH1 wildtype. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognostic Value of Immunohistochemical Biomarkers in Patients with Astrocytic Brain Tumor(Mongolian National University of Medical Sciences, 2018-09-25) ;Enkhee Ochirjav ;Bolortuya Dorj; Objectives: Astrocytoma is a common primary malignant brain tumor and it is typically associated with poor outcome. In this study, we aimed to determine role of various immunohistochemical (IHC) biomarkers and their relationship with patient prognosis. Methods: Patients who underwent surgery for astrocytic brain tumor were selected. Tissue specimens were collected from surgically removed tumors and stained by various IHC stains. All-cause mortality was chosen for study endpoint. Results: A total of 133 patients with who underwent surgery for astrocytic brain tumor were included (mean age 38±19 and 49.6% male). During follow-up, 84 patients (63%) died and the median time of death was 8 months (IQR 4; 16) after hospital discharge. Patients who died had higher tumor grade (60.7% vs. 34.7%, p<0.01). After adjustment of possible predictors, surgical type (HR=0.51, 95% CI 0.31-0.82, p<0.01), expression level of Ki67 (HR=1.02, 95% CI 1.00-1.04, p<0.05) and p53 (HR=1.01, 95% CI 1.00-1.02, p<0.05) were independently associated with long term mortality. Kaplan-Meier estimation showed overexpression of WT1 (42% vs. 52%, p<0.05) and Ki67 (27% vs. 58%, p<0.001) are associated with poor survival. Conclusion: IHC biomarkers are independently associated with long term prognosis in patients with astrocytic brain tumor. Overexpression of WT1 and Ki67 marker are associated with poor survival.
